Pathophysiology Based Therapy of Early Onset Epileptic Encephalopathies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2018-12-01

Study Completion Date

2020-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Genetic epileptic encephalopathies (EEs) are a group of very rare and severe, pharmaco-resistant epilepsy forms characterized by an early onset, e.g. first years of life, and an often severe developmental delay. Genetic defects were found in different ion channels such as potassium or sodium channels explaining well the pathological neuronal hyperexcitability leading to seizures. Further mutations were also found in proteins relevant for cell structure, DNA/RNA processing or the synaptic vesicular metabolism. Specific and individualized therapies have not been established neither in the clinical routine nor in controlled studies. The goal of this monocentric non-blinded non-placebo controlled phase IIb study is the evaluation of the effectivity of anticonvulsive drugs specifically working on the ion channels defective in some subtypes of EEs in order to establish a standard and individualized therapy for these rare diseases based on the specific genetic defect.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical-genetic Investigations in Children With Early Infantile Epilepsies

NCT01357707

Epilepsy Seizures, Infantile

COMPLETED

Genetic Basis of Idiopathic Focal Epilepsies With Cognitif Deficits

NCT00851331

Epilepsy

UNKNOWN NA

Genotype, Phenotype, and Disease Progression of Developmental Epileptic Encephalopathy With Onset Before 2 Years of Age

NCT06278428

Epilepsy; Seizure Child Development Gene Abnormality +1 more

RECRUITING

Molecular Genetic Mechanisms of Infantile Epilepsies and the Impact of Genetic Diagnosis

NCT06701084

Neonatal Epilepsy Infantile Epilepsy

RECRUITING NA

Genetic and Electrophysiologic Study in Focal Drug-resistant Epilepsies

NCT02890641

Refractory Focal Epilepsy Focal Cortical Dysplasia Hemimegalencephaly +2 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

During the study, the sodium channel blockers phenytoin and lacosamide and the potassium channel blocker kinidinsulfate will be given under standardized conditions to patients with an early onset and pharmaco-resistant genetic epilepsy with and without mutations in the potassium channels KCNT1 and KCNQ2 and the sodium channel gene SCN2A. The primary endpoint will be a significant seizure reduction under trial medication compared to baseline. Secondary endpoints will be the improvement of electroencephalographic characteristics of the respective EEs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Seizure, Epileptic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Treatment A - if no positive response: Treatment B

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Therapy regime

Two medical drugs will be administered in a predefined order (1. Phenhydan® (Phenytoin), 2. Lacosamide (Vimpat®) to investigate whether this enables an effective reduction of seizures in early onset epileptic encephalopathies..

Group Type EXPERIMENTAL

Therapy regime

Intervention Type OTHER

Patient will receive Phenytoin, if no success is obtained, Vimpat is given. In case of success after one of the treatments, the endpoint is reached. Success is defined as reduction of seizures to 50% compared to baseline.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Therapy regime

Patient will receive Phenytoin, if no success is obtained, Vimpat is given. In case of success after one of the treatments, the endpoint is reached. Success is defined as reduction of seizures to 50% compared to baseline.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

two medical products given in a predefined order

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* highly active epilepsy (≥ 1 seizure per day)
* epilepsy with onset 0-3 months of age
* pharmaco-resistant epilepsy (2 or more standard anticonvulsive medications tried before)
* recently max. two stable anticonvulsive drugs for minimum 4 days before study start
* patients under continuous monitoring control
* patients younger than 1 year of age

Exclusion Criteria

* high grade cardial rhythm disorders
* severe liver, renal and electrolyte blood parameter changes
* metabolic or lesional origin of epilepsy (metabolic screening results and cranial MRI available)
* parallel participation in other studies (must be finished two month before study start)
* missing informed consent

Maximum Eligible Age

12 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No